卵巢癌 (OC) 患者会出现腹水，腹水在腹膜腔内积聚，是肿瘤在腹膜腔内播散的迹象。这种体液的研究不足，主要是关于肿瘤进展过程中形成的腹水，这些腹水没有诊断价值，因此被丢弃。我们进行了一项发现性蛋白质组学研究，以确定 OC 患者腹水上清液中的新生物标志物。在这项初步研究中，我们分析了少量的 OC 腹水，以强调在治疗过程中不丢弃此类生物材料的重要性，这对于 OC 管理可能很有价值。我们的研究结果表明，OC 恶性腹水 (MAF) 表现出一种增殖环境，可促进 OC 细胞的生长，从而利用替代营养来源（例如胆固醇途径）改变代谢途径。此外，治疗期间从患者排出的 OC 腹水显示出免疫抑制环境，IL-4 和 IL-13 信号通路中的蛋白质上调，而 MHC-II 信号通路中的蛋白质下调。这项初步研究确定了 OC 背景下的一种新蛋白质（跨膜蛋白 132A），值得在更广泛的患者样本队列中进行更好的探索。 OC 患者的 MAF 蛋白质组学特征为了解疾病进展过程中癌细胞的代谢动力学提供了独特的见解，这些信息可用于制定更有效的治疗策略。© 2024 作者。由 Elsevier B.V. 出版

Ovarian cancer (OC) patients develop ascites, an accumulation of ascitic fluid in the peritoneal cavity anda sign of tumour dissemination within the peritoneal cavity. This body fluid is under-researched, mainly regarding the ascites formed during tumour progression that have no diagnostic value and, therefore, are discarded. We performed a discovery proteomics study to identify new biomarkers in the ascites supernatant of OC patients. In this preliminary study, we analyzed a small amount of OC ascites to highlight the importance of not discarding such biological material during treatment, which could be valuable for OC management. Our findings reveal that OC malignant ascitic fluid (MAF) displays a proliferative environment that promotes the growth of OC cells that shift the metabolic pathway using alternative sources of nutrients, such as the cholesterol pathway. Also, OC ascites drained from patients during treatment showed an immunosuppressive environment, with up-regulation of proteins from the signaling pathways of IL-4 and IL-13 and down-regulation from the MHC-II. This preliminary study pinpointed a new protein (Transmembrane Protein 132A) in the OC context that deserves to be better explored in a more extensive cohort of patients' samples. The proteomic profile of MAF from OC patients provides a unique insight into the metabolic kinetics of cancer cells during disease progression, and this information can be used to develop more effective treatment strategies.© 2024 The Authors. Published by Elsevier B.V.